Targeting the cytotoxic T lymphocyte antigen 4 (CTLA4) or PD-1/PD-L1 pathways checkpoint inhibitors have not been effective as a single agent in MM patients. The gene discussed is PDCD1; the disease is Miyoshi myopathy.